Aligos Therapeutics (STU:5WK0) Other Stockholders Equity: €-0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5WK0 Aligos Therapeutics Inc STU:5WK0
44 GF Score
Price €6.21
GF Value €29.32
! 6 Warning Signs
View Full Analysis

What is Aligos Therapeutics Other Stockholders Equity?

Aligos Therapeutics STU:5WK0 +26.61% 44 Other Stockholders Equity is €-0.00 Mil as of Jun. 2026. GuruFocus rates STU:5WK0 with a GF Score™ of 44/100 and a GF Value™ of €29.32. The stock has 6 warning signs investors should review.

Aligos Therapeutics's Other Stockholders Equity for the quarter that ended in Jun. 2026 was €-0.00 Mil.

Aligos Therapeutics's quarterly Other Stockholders Equity declined from Dec. 2025 (€-0.00 Mil) to Mar. 2026 (€-0.00 Mil) but then increased from Mar. 2026 (€-0.00 Mil) to Jun. 2026 (€-0.00 Mil).

Aligos Therapeutics's annual Other Stockholders Equity declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€-0.00 Mil) and declined from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Aligos Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics Other Stockholders Equity Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial -0.00 -0.00 0.00 -0.00 -0.00

Aligos Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.00 -0.00
STU:5WK0
44GF Score
Aligos Therapeutics Inc STU:5WK0
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aligos Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-0.00 Mil mean?
Aligos Therapeutics (STU:5WK0) has a Other Stockholders Equity of €-0.00 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Aligos Therapeutics and its competitors.
Is Aligos Therapeutics' Other Stockholders Equity too high?
Aligos Therapeutics' current Other Stockholders Equity is €-0.00 Mil. Overall, Aligos Therapeutics has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Other Stockholders Equity compare to CRVO and PVCT?
Aligos Therapeutics' Other Stockholders Equity of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current Other Stockholders Equity is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Aligos Therapeutics (STU:5WK0) has a current Other Stockholders Equity of €-0.00 Mil. The stock's GF Value™ is €29.32, compared to a current price of €6.21 — trading 78.8% below its estimated fair value. The current Other Stockholders Equity is €-0.00 Mil. Aligos Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Aligos Therapeutics (STU:5WK0), the current Other Stockholders Equity is €-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (STU:5WK0) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued. The current stock price of €6.21 is trading 78.8% below its estimated GF Value™ of €29.32.

Key valuation signals for STU:5WK0:

  • Other Stockholders Equity: €-0.00 Mil
  • GF Value™: €29.32 vs. price of €6.21 (78.8% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the STU:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges ALGS:USA
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
44GF Score

Get the complete analysis for STU:5WK0

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.21
Price
€29.32
GF Value